iTeos And GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug And Dostarlimab In Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer; Primary Endpoints Of The Trial Are Progression Free Survival And Overall Survival
Portfolio Pulse from Benzinga Newsdesk
iTeos Therapeutics and GSK have initiated the GALAXIES Lung-301 Phase 3 study to assess the efficacy of belrestotug and dostarlimab in treating previously untreated, unresectable, locally advanced or metastatic PD-L1 selected non-small cell lung cancer. The primary endpoints are progression-free survival and overall survival.
June 17, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK, in partnership with iTeos, has initiated a Phase 3 study for belrestotug and dostarlimab. Success in this trial could enhance GSK's oncology portfolio and revenue streams.
GSK's involvement in the Phase 3 study with iTeos could lead to a significant enhancement of its oncology portfolio. Successful trial results could result in new revenue streams and strengthen its market position in oncology.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
iTeos Therapeutics has initiated a Phase 3 study for its immuno-oncology therapeutics, which could significantly impact its future revenues and market position if successful.
The initiation of a Phase 3 study is a critical milestone for iTeos Therapeutics. Positive results could lead to regulatory approval and commercialization, significantly boosting the company's revenues and market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100